Collagen V Antibody [L8G6] | Primary Antibodies

Application: Reactivity: Mouse, Rat, Human

Lane 1: Rat articular cartilage

Usage Information

Dilution
WB1:1000

Application
WB

Reactivity
Mouse, Rat, Human

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
184 kDa 145 kDa,32 kDa, 36 kDa
^*Why do the predicted and actual molecular weights differ? The following reasons may explain differences between the predicted and actual protein molecular weight. Post-translational modifications(e.g., phosphorylation, glycosylation); Splice variants and isoforms; Relative charge; Multimerization.

Datasheet & SDS

Biological Description

Specificity
Collagen V Antibody [L8G6] detects endogenous levels of total Collagen V.

Clone
L8G6

Synonym(s)
Collagen alpha‑2(V) chain; COL5A2

Background
Collagen V (COLV) is a minor fibrillar collagen that forms heterotrimeric molecules of two α1(V) and one α2(V) chains and acts as a dominant regulator of collagen I fibrillogenesis and extracellular matrix organization in tissues such as skin, tendon, cornea, and sclera. It co assembles with collagen I into heterotypic fibrils, where its partially processed N terminal domain protrudes from the fibril surface and constrains collagen I fibril diameter, packing, and lateral alignment, thereby governing the biomechanical properties and scattering characteristics of connective tissues. In the matrix, COLV interacts with additional collagens, proteoglycans such as decorin and biglycan, and structural proteins that fine tune fibril architecture and mechanical anisotropy, while also engaging cell surface integrins to modulate focal adhesion formation, cytoskeletal tension, and mechanotransduction in fibroblasts and other stromal cells. Collagen V also interfaces with TGF β signaling and Wnt/β catenin pathways, influencing progenitor proliferation, differentiation, and matrix remodeling during development and repair, and loss of function mutations in COL5A1 or COL5A2 disrupt collagen V–dependent fibrillogenesis, leading to classic Ehlers Danlos syndrome with skin hyperextensibility, abnormal scarring, and joint hypermobility. In fibrotic and pathological states, aberrantly elevated collagen V expression accompanies excessive deposition of fibrillar collagens and matrix stiffening in lung, kidney, skin, and adipose tissues, so that collagen V dependent matrix organization and mechanosignaling are ultimately dysregulated in both hereditary connective tissue diseases and acquired fibrotic disorders.

Background

Collagen V (COLV) is a minor fibrillar collagen that forms heterotrimeric molecules of two α1(V) and one α2(V) chains and acts as a dominant regulator of collagen I fibrillogenesis and extracellular matrix organization in tissues such as skin, tendon, cornea, and sclera. It co assembles with collagen I into heterotypic fibrils, where its partially processed N terminal domain protrudes from the fibril surface and constrains collagen I fibril diameter, packing, and lateral alignment, thereby governing the biomechanical properties and scattering characteristics of connective tissues. In the matrix, COLV interacts with additional collagens, proteoglycans such as decorin and biglycan, and structural proteins that fine tune fibril architecture and mechanical anisotropy, while also engaging cell surface integrins to modulate focal adhesion formation, cytoskeletal tension, and mechanotransduction in fibroblasts and other stromal cells. Collagen V also interfaces with TGF β signaling and Wnt/β catenin pathways, influencing progenitor proliferation, differentiation, and matrix remodeling during development and repair, and loss of function mutations in COL5A1 or COL5A2 disrupt collagen V–dependent fibrillogenesis, leading to classic Ehlers Danlos syndrome with skin hyperextensibility, abnormal scarring, and joint hypermobility. In fibrotic and pathological states, aberrantly elevated collagen V expression accompanies excessive deposition of fibrillar collagens and matrix stiffening in lung, kidney, skin, and adipose tissues, so that collagen V dependent matrix organization and mechanosignaling are ultimately dysregulated in both hereditary connective tissue diseases and acquired fibrotic disorders.

References
https://pubmed.ncbi.nlm.nih.gov/26910848/ https://pubmed.ncbi.nlm.nih.gov/9042913/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%